HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $100 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ: ARWR ) with a Buy and maintains $100 price target.